Welcome to our dedicated page for Alphatec Hldgs news (Ticker: ATEC), a resource for investors and traders seeking the latest updates and insights on Alphatec Hldgs stock.
Alphatec Holdings, Inc. develops medical technology for spine surgery, with a business centered on procedural spine solutions, surgical instrumentation, imaging, navigation and informatics. Company updates commonly address surgical revenue trends, EOS revenue, surgeon adoption, product launches such as Valence and EOS Insight, and the continued development of its InformatiX platform through subsidiaries including Alphatec Spine, EOS imaging and SafeOp Surgical.
Recurring developments also include financing actions, credit-facility activity, strategic partnerships tied to spinal fusion and regenerative technology, profitability metrics and annual outlook updates. Governance items, including board composition changes, appear alongside operating results and capital-structure announcements.
Alphatec Holdings (Nasdaq: ATEC) reported second quarter 2026 total revenue of $214 million, up 15% year-over-year, with surgical revenue of $196 million, up 17% on 20% case volume growth. GAAP gross margin was 72.2% and non-GAAP gross margin 72.5%.
Net new surgeon users increased 24%. GAAP net loss was $26 million, while non-GAAP net income was $11 million. Adjusted EBITDA reached $36 million, a 16.8% margin and 420 bps expansion year-over-year. Ending cash was $119 million, with positive quarterly and trailing twelve‑month free cash flow.
ATEC reaffirmed its 2026 revenue outlook of approximately $882 million (about $805 million surgical, $77 million EOS), implying ~15% total and ~17% surgical revenue growth, and raised 2026 adjusted EBITDA guidance to ~$140 million, while continuing to expect at least $20 million of free cash flow.
Alphatec Holdings (Nasdaq: ATEC) will participate in several upcoming investor events. Management will hold one-on-one meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026, present at the 19th Annual Piper Sandler MedTech and Diagnostics California Bus Tour on August 19, 2026 at 9:45 a.m. PT at The Ritz-Carlton Laguna Niguel, and host meetings and a fireside chat at the 2026 Wells Fargo Healthcare Conference on September 9, 2026 at 3:45 p.m. ET at Encore Boston Harbor. Webcast access, if available, will be posted in ATEC’s Investor Relations website.
ATEC also approved 108,630 restricted stock units across 36 grants to non-executive new employees under its 2016 Employment Inducement Award Plan, vesting in four equal annual installments and fully upon a change of control, subject to continued employment.
Alphatec Holdings (Nasdaq: ATEC) will report its second quarter 2026 financial results on August 4, 2026, after the market close. Management will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET with a question‑and‑answer session for registered analysts.
The webcast and a 12‑month replay will be accessible through the Investor Relations Events & Presentations section of ATEC’s corporate website. Analysts must register in advance via the provided link to receive unique access details.
Alphatec Holdings (Nasdaq: ATEC) entered an inaugural syndicated bank facility on May 5, 2026 consisting of a $125 million revolving credit facility and a $175 million Term Loan A, led by JPMorgan Chase and TD Securities.
The facility refinances prior term and ABL lenders, carries interest at SOFR+275 bps, extends maturities to 2031, is expected to cut interest expense by more than $6 million annually and may save over $35 million over its life; it includes a $150 million accordion for future growth.
Alphatec (Nasdaq: ATEC) reported Q1 2026 results: $192M total revenue, surgical revenue of $178M (+17% YoY), GAAP net loss of $34M, and non-GAAP adjusted EBITDA of $21M (11% margin). Ending cash totaled $140M and trailing twelve-month free cash flow improved to $7M. The company refinanced debt with a new bank facility, cutting interest expense by >$6M annually and extending maturities to 2031.
Alphatec (Nasdaq: ATEC) will report Q1 2026 financial results on May 5, 2026 after market close and will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET.
Analysts must register in advance to join the Q&A; a replay will be available on the company investor relations site for twelve months. Management will attend the Bank of America 2026 Healthcare Conference on May 12. The compensation committee approved 59,431 RSUs for 43 new employees, vesting annually over four years and fully vesting on a change of control.
Alphatec (Nasdaq: ATEC) reported full-year 2025 total revenue of $764 million, up 25% year-over-year, with GAAP gross margin of 70% and non-GAAP adjusted EBITDA of $93 million (12% margin). The company launched the Valence intraoperative platform and provided 2026 guidance of ~$890 million revenue and adjusted EBITDA of ~$134 million.
Key cash metrics: ending cash $161 million, positive free cash flow of $8 million in Q4 and $3 million for FY2025. GAAP net loss was ($143) million for 2025.
Alphatec Holdings (Nasdaq: ATEC) and Theradaptive announced a definitive strategic partnership on Jan. 12, 2026 granting ATEC exclusive U.S. commercial rights to Theradaptive's OsteoAdapt® osteoinductive bone graft for spinal fusion. The agreement is structured with a combination of upfront and milestone payments and a perpetual royalty framework intended to deliver long-term value in the spine market. Concurrently, Theradaptive initiated a Series B financing to accelerate expansion of its proprietary protein-engineering platform across global therapeutic applications.
Alphatec Holdings (Nasdaq: ATEC) reported preliminary, unaudited 2025 results with total revenue of $763.4M–$764.4M (≈25% growth) and surgical revenue of $686.3M–$687.0M (26% growth; volume +24%, revenue per procedure +2%). The company reaffirmed 2025 adjusted EBITDA of $91M and reported cash of ≈$161M and Q4 free cash flow of $6M–$8M. ATEC acquired exclusive U.S. distribution rights for Theradaptive’s OsteoAdapt (next‑gen rhBMP‑2, Phase II). For 2026 the company guides $890M total revenue (+≈17%), surgical revenue ≈$805M, EOS ≈$85M, adjusted EBITDA ≈$130M, and expected free cash flow ≈$20M. Results are preliminary and subject to audit.
Alphatec Holdings (Nasdaq: ATEC) announced the passing of board member Jeffrey P. Rydin at age 59 on November 3, 2025 after a lengthy illness.
Rydin joined ATEC as a Special Advisor in September 2016, was appointed to the Board in June 2017, and was credited with helping transform the company’s sales channel. He had nearly three decades of medical device and healthcare experience, including senior sales roles at Ellipse Technologies, NuVasive, and DePuy Spine. CEO Pat Miles paid tribute to Rydin’s leadership, commitment, and family devotion and offered the company’s condolences to his wife Melissa and sons Spencer and Griffin.